Sai Life Sciences Ltd.

SAILIFE

₹770.0

2.63% (19.75)

Market Cap

₹16,075 Cr.

P/E

94.49

About

Sai Life Sciences is a fully-integrated organization offering services across the drug discovery, development, and manufacturing value chain for small molecule new chemical entities. They cater to glo… Read more

Sai Life Sciences is a fully-integrated organization offering services across the drug discove… Read more

Low

636

52W Range

High

809

Timeline

Key company specific updates

Company Timeline

Custom financial statementNew

Edit rows

In Rs. Cr.	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025

In Rs. Cr.	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Balance sheet
Net Block	203	272	307	373	641	701	972	1,037	1,180	1,196
Shareholders Funds	274	321	367	720	794	863	879	888	975	2,128
Profit & Loss
Operating Profit	79.90	77.72	98.69	176	168	167	125	169	287	498
Net Sales	425	442	526	695	726	760	870	1,217	1,465	1,842
Cash flow
Cash from Operating Activity	30.19	18.53	48.97	129	116	-36.38	105	219	263	314
Net Capex (est)	26.15	70.63	59.47	158	272	262	108	71.17	181	369
Ratios
ROCE (%)	18.04	18.62	17.07	15.57	13.86	9.44	4.35	6.86	12.93	—
ROE (%)	12.75	14.81	11.46	10.21	9.61	7.08	0.71	1.12	8.49	—

Forensics

9 Yes

Positive for this company

2 Neutral

Neutral for this company

4 No

Negative for this company

2 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Other Income

Other income is not affecting ratios of the company
Pledge

Promoters have not pledged a significant portion of their holding
Retail Holding

Retail has been selling the stock which is usually a good time to buy
Revenue Recognition

Company is converting accounting profit to cash
Depreciation Effect

Company is depreciating a greater percentage of assets. this is contributing to a reduction in net profit
Promoter Holding

Promoter has not sold any shares in the last 90 days

Price & Performance

Capex vs ROCE

Company has maintained it roce despite making significant capex
ROE

Asset turnover is responsible for roe increase over last 10 years
Working Capital

Working capital of the company seems to be under control
Balance Sheet Strength

Balance sheet of the company is strong. but it might have issues paying it suppliers
Share price

Share price has decreased over last 10 years more due to earnings
Debt

Company might have issues servicing its debt
Margin Stability

Margins of the company are volatile
ROCE Strength

Roce of the company is not consistently strong
Current vs Historic Valuation

Unable to calculate due to limited data
Sales Growth

Unable to calculate due to limited data

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Asset Break-Up - Geography Wise

Peer Comparison

Peer Name	Latest Price	PE	Market cap(Cr)	Prom Holding(%)	YoY Qtly Sales(%)	ROCE (%)	ROE (%)
Sai Life Sciences	770	94.49	16,075	35.17	31.94	12.93	8.49
Divi's Lab	6,667	80.82	1,77,076	51.89	12.24	15.28	11.79
Cohance Lifesciences	1,004.5	143.37	38,404	50.1	58.95	19.24	14.64
Syngene Internation.	653.1	52.99	26,292	52.74	11.03	13.67	11.98

FAQs on Sai Life Sciences Ltd. Business

What does Sai Life Sciences do?

Sai Life Sciences is a pure play fully-integrated, innovator-focused, contract research, development and manufacturing organization. It provides end-to-end services across the drug discovery, development and manufacturing value chain for small molecule new chemical entities to global pharmaceutical innovators companies and biotechnology firms. It possesses both (a) discovery / contract research and (b) chemistry, manufacturing, and control / contract development and manufacturing organization capabilities.

Who are the competitors of Sai Life Sciences?

Sai Life Sciences major competitors are Divi's Lab, Cohance Lifesciences, Syngene Internation..
Market Cap of Sai Life Sciences is ₹15,631 Crs.
While the median market cap of its peers are ₹38,475 Crs.

Is Sai Life Sciences financially stable compared to its competitors?

Sai Life Sciences seems to be less financially stable compared to its competitors.
Altman Z score of Sai Life Sciences is 8.83 and is ranked 4 out of its 4 competitors.

View FAQ's On Shareprice

Company Filing

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	May	Dec
Investor Presentation	May	Dec
Conference Call	Mar	Dec
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Ideas Dashboard

Timeline

Watchlist

Portfolio

Alerts

Research

Stock Screener

Market

Raw Material

Sai Life Sciences Ltd.